How new technologies are transforming pharmacovigilance and improving patient safety
Digital Innovation in Pharmacovigilance
Digital Innovation in Pharmacovigilance
This whitepaper explores the hype versus the current reality for AI technologies within pharmacovigilance and examines the main business use cases today plus the potential gains for biopharmaceutical safety teams. We provide a decision guide to help assess whether an AI approach is appropriate, or whether more established methods with demonstrated benefits – such as rules-based automation – are better suited for the job at hand.
Crucially, the paper outlines why a balanced approach to people, processes and technology will be vital if the industry is to succeed in maximizing the AI opportunity. This includes the need to critically appraise the utility of disruptive technologies across functions and the safety lifecycle before they are implemented – and, importantly, to assess whether they can deliver a measurable impact and genuinely enhance patient safety and move the needle on the core strategic aims of the business.